Participants receive a low dose of Tranexamic acid (10mg/kg) administered slowly over 5 minutes intravenously (iv) 10 minutes prior to skin incision in elective caesarean section with prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby.

Participants receive prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby

Post Partum Hemorrhage

TXA (10mg/kg) solution for injection from the vial will be diluted with 100 - 200ml electrolyte solution such as Normal Saline, Ringers solution, dextrose/water for injection on the same day it is to be used (i.e. when anaesthetist notes the patient has been randomized to receive TXA). Intravenous administration should be at a rate of 100mg or fraction thereof over at least 1 minute - usually at least 5 minutes. Standard practice is to administer over 20 minutes. Administration is to be done at least 10 minutes prior to skin incision.

Tranexamic Acid

5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.

Oxytocin

Harare Central Hospital

Parirenyatwa Group of Hospitals

Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section

Blood loss equal to or exceeding 1000ml following elective caesarean section

Blood loss during caesarean section based on visual estimation and calculation.

Requirement by participant of blood transfusion

Use of additional uterotonics such as an oxytocin infusion or prostaglandin use

Any adverse effects related to tranexamic acid use

Incidence of emergency surgical procedures to manage any postpartum haemorrhage that occurs

Duration of participants' stay in hospital

Apgar scores out of 10 at 1 minute and 5 minute

Reason for and number of days from admission to and duration of stay in neonatal unit

It is undecided whether the IPD will be made available to other researchers. Clearance is required first from ethical bodies and supervisors

Chipo Gwanzura, MD

Junior Registrar

University of Zimbabwe

Randomized control trial with two arms. Participants receive either 10mg/kg of TXA 10 minutes prior to elective caesarean section with prophylactic oxytocin administration after delivery of the baby, versus prophylactic oxytocin alone after delivery of the baby.

Trial is an open label randomized control trial

Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage
AND
Patients will have 1gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) intravenously infused over 10 minutes within 3 hours of symptom presentation and another 1 gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) infused over 8 hours.

Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage
AND
Patients will 100ml of normal saline 0.9% intravenously infused over 10 minutes within 3 hours of symptom presentation and another 100ml of normal saline 0.9% infused over 8 hours.

Stroke Hemorrhagic

Intracerebral Haemorrhage

Transamine is an antifibrinolytic medication given systemically via the intravenous route

Kwong Wah Hospital

Tranexamic Acid for Spontaneous Acute Cerebral Hemorrhage Trial

Randomized, Double-blind, Placebo-controlled Trial to Investigate the Effectiveness of Early Intravenous Tranexamic Acid in Limiting Hematoma Expansion in Patients With Spontaneous Intracerebral Hemorrhage

Intracerebral hematoma volume (ml) as assessed by CT brain scan.

All-cause mortality within 30 days of admission

Ischemic stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis

Rate of seizures within 30 days of stroke

Intolerable gastrointestinal symptoms such as dyspepsia, diarrhea, vomiting.
Allergic reaction to TXA.

Need for operative management of the hemorrhagic stroke

Peter Woo Yat Ming

Doctor

Randomised placebo-controlled parallel group clinical trial

Intravenous normal saline or transamine will be administered to subjects. Both will be of equal volume, colour and in similar intravenous fluid packaging.
The outcomes assessor will be unaware of the subject group allocation.

menorrhagia/seizures

Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section

Tranexamic Acid for Spontaneous Acute Cerebral Hemorrhage Trial

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen